Brief Admission for Adolescents Who Self-harm

Sponsor
Region Skane (Other)
Overall Status
Recruiting
CT.gov ID
NCT04962373
Collaborator
Lund University (Other)
75
1
52
1.4

Study Details

Study Description

Brief Summary

There is still no consensus on how to manage suicidal behavior in youth with recurrent self-harm at times when the risk for suicide is imminent (1). Brief Admission (BA) has evolved as a promising crisis intervention for adults with self-harm (2). The characteristics of BA is different from other types of admission, being focused on prevention through increased autonomy and self-care, based on structured and voluntary brief self-referrals to hospital (3). As a result of a randomized controlled trial, BA is since January 2019, continuously offered to adults with self-harm at risk for suicide in Skåne (4). Parallel to this clinical trial, the method has been adapted to work in a psychiatric setting for adolescents. At present 24 adolescents have access to the method in Skåne. Clinical experiences from staff are promising, however, the lived experiences have not been collected in a standardized way.

The aim of the present study is to gather information on how BA in its present, standardized form works for adolescents, their loved ones and staff working at the ward providing BA. This will be done through semi-structured interviews with:

  1. Adolescents using BA and their loved ones

  2. Staff working at the ward providing BA. Data will be analyzed with qualitative analysis (5, 6). The ultimate aim is to use these results to optimize the current standardized version of BA for adolescents in order to test in a randomized clinical trial.

Condition or Disease Intervention/Treatment Phase
  • Other: Semi-structured interviews

Study Design

Study Type:
Observational
Anticipated Enrollment :
75 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Brief Admission by Self-referral for Adolescents Who Self-harm, at Risk for Suicide. A Qualitative Study to Optimise and Standardise the Intervention
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Adolescents

Adolescents with a contract for Brief admission by self-referral

Other: Semi-structured interviews
Each participant will attend a 30-60 minute semi-structured interview conducted by the CI

Parents

Parents to adolescents with a contract for Brief admission by self-referral

Other: Semi-structured interviews
Each participant will attend a 30-60 minute semi-structured interview conducted by the CI

Staff

Health care providers who work with adolescents with a contract for Brief admission by self-referral

Other: Semi-structured interviews
Each participant will attend a 30-60 minute semi-structured interview conducted by the CI

Outcome Measures

Primary Outcome Measures

  1. Perceived effective components of Brief Admission for adolescents [60mins]

    Qualitative data from interviews

  2. Potential adaptations of the method to better fit adolescents [60mins]

    Qualitative data from interviews

  3. Areas where Brief Admission have the most prominent perceived effects in adolescents [60mins]

    Qualitative data from interviews

Eligibility Criteria

Criteria

Ages Eligible for Study:
13 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Sample 1:
Inclusion Criteria:
  • Adolescents with an active BA contract

  • At least 13 years of age.

  • Able to consent to study participation through written and oral information.

  • Consent from caregivers

  • Given consent to participate

Exclusion Criteria:
  • Below the age of 13.
Sample 2:
Inclusion Criteria:
  • Parents to adolescents with an active BA contract

  • At least 18 years of age.

  • Able to consent to study participation through written and oral information.

  • Given consent to participate

Exclusion Criteria:
  • None
Sample 3:
Inclusion Criteria:
  • Staff working with adolescents with an active BA contract

  • At least 18 years of age.

  • Able to consent to study participation through written and oral information.

  • Given consent to participate

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 Psykiatri och habilitering, Region Skåne Lund Skåne Sweden 22185

Sponsors and Collaborators

  • Region Skane
  • Lund University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Sofie Westling, Principal Investigator, Region Skane
ClinicalTrials.gov Identifier:
NCT04962373
Other Study ID Numbers:
  • 2020-01840
First Posted:
Jul 15, 2021
Last Update Posted:
Jul 16, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2021